In short
This article discusses a clinical trial investigating the use of BMS-986315, a novel drug, in combination with nivolumab and chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). The study aims to assess the effectiveness and safety of this combination therapy compared to standard treatment approaches in patients with stage IV or recurrent NSCLC.
At a glance
- Study Type
- Randomized, double-blind, Phase 2 clinical trial
- Primary Objective
- Evaluate efficacy and safety of BMS-986315 plus nivolumab with chemotherapy vs. nivolumab with chemotherapy
- Target Population
- Patients with first-line Stage IV or recurrent NSCLC
- Treatment Arms
- Multiple arms testing different dose levels of BMS-986315 with nivolumab and chemotherapy
- Primary Outcome Measures
- Safety assessments (Part 1), Objective Response Rate (Part 2)
- Secondary Outcome Measures
- Progression-Free Survival, Duration of Response, pharmacokinetics, immunogenicity
- Key Drugs
- BMS-986315, Nivolumab, Pemetrexed, Carboplatin, Paclitaxel
What is BMS-986315?
BMS-986315 is a new drug being developed for the treatment of cancer. It's also known as Anti-NKG2A, which gives us a clue about how it works in the body. This medication is currently being studied in clinical trials to determine its effectiveness and safety in treating a specific type of lung cancer.
What condition does BMS-986315 target?
The primary focus of the current research on BMS-986315 is its potential use in treating Non-Small Cell Lung Cancer (NSCLC). Specifically, the drug is being studied for patients with Stage IV or recurrent NSCLC. NSCLC is the most common type of lung cancer, accounting for about 80-85% of all lung cancer cases. Stage IV means the cancer has spread to other parts of the body, while recurrent means the cancer has come back after initial treatment.
How does BMS-986315 work?
While the exact mechanism of BMS-986315 isn't fully described in the available information, its alternative name "Anti-NKG2A" suggests it targets a specific protein in the immune system. NKG2A is a receptor found on certain immune cells. By blocking or modifying this receptor, BMS-986315 may help enhance the body's natural ability to fight cancer cells.
Current Clinical Trial
BMS-986315 is currently being studied in a clinical trial. This trial is officially titled "A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)". Let's break down what this means:
- Randomized: Participants are randomly assigned to different treatment groups.
- Double-blind: Neither the participants nor the researchers know who is receiving which treatment, which helps prevent bias.
- Phase 2: This phase tests the drug in a larger group of people to see if it works and to further evaluate its safety.
- First-line Treatment: This means the treatment is being studied as the initial treatment for newly diagnosed patients.
Combination Therapy Approach
In this study, BMS-986315 is not being used alone. Instead, it's being tested in combination with other treatments:
- Nivolumab: Also known as Opdivo or BMS-936558, this is an immunotherapy drug already approved for various cancers.
- Platinum-based doublet chemotherapy (PDCT): This includes drugs like pemetrexed, cisplatin, carboplatin, and paclitaxel, which are standard chemotherapy medications for NSCLC.
The idea behind this combination approach is to potentially enhance the effectiveness of treatment by attacking the cancer in multiple ways.
Study Design and Objectives
The study is divided into two parts:
- Part 1: This part focuses on safety and finding the right dose of BMS-986315. It looks at different dose levels (DL1 and DL2) of BMS-986315 in combination with nivolumab and chemotherapy.
- Part 2: This part compares the effectiveness and safety of BMS-986315 (at the dose determined in Part 1) plus nivolumab and chemotherapy against nivolumab and chemotherapy alone.
Potential Benefits and Outcomes
The study aims to measure several important outcomes:
- Objective Response Rate (ORR): This measures how many patients see their tumors shrink or disappear with treatment.
- Progression Free Survival (PFS): This looks at how long patients live without their cancer getting worse.
- Duration of Response (DOR): This measures how long the positive effects of treatment last.
- Disease Control Rate (DCR): This includes patients whose disease improves, stays stable, or grows more slowly with treatment.
Safety Monitoring
The study closely monitors the safety of BMS-986315 and the combination treatment. Researchers are tracking:
- Adverse Events (AEs): Any unfavorable medical occurrences during treatment.
- Treatment-related AEs (TRAEs): Side effects believed to be caused by the study treatments.
- Serious AEs (SAEs): More severe or life-threatening side effects.
- Dose Limiting Toxicities (DLTs): Side effects severe enough to limit the dose of medication that can be given.
The study also looks at how the body processes BMS-986315 (pharmacokinetics) and whether patients develop antibodies against the drug, which could affect its effectiveness.